Late liver-related mortality from complications of transfusion-acquired hepatitis C

Hepatology

Volumn 41, Issue 4, 2005, Pages 819-825

  Kamitsukasa, Hiroshi ^a,c   Harada, Hideharu ^a   Tanaka, Hideo ^b   Yagura, Michiyasu ^a   Tokita, Hajime ^a   Ohbayashi, Akira ^a  

^a TOKYO NATIONAL HOSPITAL   (Japan)

^b OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^c NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C ANTIBODY; VIRUS RNA;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD TRANSFUSION; CAUSE OF DEATH; CHRONIC HEPATITIS; COHORT ANALYSIS; CONTROLLED STUDY; ELDERLY CARE; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SURVIVAL; TUBERCULOSIS; VARICOSIS;

EID: 16244380804     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.20648     Document Type: Article

References (26)

1. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa k, Nakano Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. HEPATOLOGY 1990;12:671-675.
2. Gordon SC, Elloway RS, Long JC, Dmuchowski CF. The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use. HEPATOLOGY 1993;18:1338-1343.
3. Tong MJ, el-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332:1463-1466.
4. Yano M, Kumada H, Kage M, Ikeda K, Shimamatu K, Innoue O, et al. The long-term pathological evolution of chronic hepatitis C. HEPATOLOGY 1996;23:1334-1340.
5. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Harter D, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. HEPATOLOGY 1998;28:1687-1695.
6. Percico M, Percico E, Suozzo R, Conte S, Seta MD, Coppola L, et al. Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000;118:760-764.
7. Martinot-Peignoux M, Boyer N, Cazals-Hatem D, Pham BN, Gervais A, Breton LV, et al. Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. HEPATOLOGY 2001;34:1000-1005.
8. Casiraghi MA, Paschale MD, Romano L, Biffi L, Assi A, Binelli G, et al. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. HEPATOLOGY 2004;39:90-96.
9. Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, et al. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med 1999;341:866-870.
10. Rodger AJ, Roberts S, Lanigan A, Bowden S, Brown T, Crofts N. Assessment of long-term outcomes of community-acquired hepatitis C infection in a cohort with sera stored from 1971 to 1975. HEPATOLOGY 2000;32:582-587.
11. Wiese M, Berr F, Lafrenz M, Porst H, Oesen U. Low frequency of cirrhosis in a hepatitis C (genotype Ib) single-source outbreak in Germany: a 20-year multicenter study. HEPATOLOGY 2000;32:91-96.
12. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999;340:1228-1233.
13. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000;284:450-456.
14. Seeff LB, Hollinger B, Alter HJ, Wright EC, Cain CMB, Buskell ZJ, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. HEPATOLOGY 2001;33:455-463.
15. Kitamoto O, Shimizu S, Naruto H, Takayama H. The research on post-transfusion hepatitis (in Japanese). Acta Hepatologica Japonica 1962;4:23-28.
16. Okuda K: Liver cancer. In: Zuckerman AJ, Thomas HC, eds. Viral Hepatitis-Scientific Basis and Clinical Management. London: Churchill Livingstone, 1993:269-281.
17. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
18. Okamoto H, Okada S, Sugiyama Y, Tanaka T, Sugai Y, Akahane Y, et al. Detection of hepatitis C virus RNA by a two-stage polymerase chain reaction with two pairs of primers deduced from the 5′-noncoding region. Jpn J Exp Med 1990;60:215-222.
19. Shiozawa M: Pulmonary tuberculosis (in Japanese). In: Kitamoto O, ed. The Series of Internal Medicine. Vol. 7. Tokyo: Nankodo, 1972:197-217.
20. National Institutes of Health consensus development conference statement: Management of hepatitis C: 2002-June 10-12, 2002. HEPATOLOGY 2002;36(Suppl):S3-S20.
21. Kiyosawa K. The trend of liver cirrhosis as a precancerous condition (in Japanese). In: The Japan Society of Hepatology, Ed. A White Paper of Liver Cancer. Tokyo: The Japan Society of Hepatology, 1999:33-37.
22. Hamada H, Yatsuhashi H, Yano K, Daikoku M, Arisawa K, Inoue O, et al. Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. Cancer 2002;95:331-339.
23. Liver Cancer Study Group of Japan. Survey and follow-up study of primary liver cancer in Japan (Report 14) (in Japanese). Acta Hepatologica Japonica 2000;41:799-811.
24. De Vos Irvine H, Goldberg D, Hole DJ, McMenamin J. Trends in primary liver cancer. Lancet 1998;351:215-216.
25. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001;34:730-739.
26. Kage M, Shimamatu K, Nakashima E, Kojiro M, Inoue O, Yano M. Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: morphometric analysis of repeated biopsies. HEPATOLOGY 1997;25:1028-1031.